Valerie Sabourin

Valerie Sabourin

Auto-generated profile, based on publicly available information

Valerie Sabourin

Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2025 in Science Advances
Verified
Journal Article
Open access
JHJohn Heath
John Heath
RARyuhjin Ahn
Ryuhjin Ahn
VSValerie Sabourin
Valerie Sabourin
YIYoung Kyuen Im
Young Kyuen Im
SRSabrina Rezzara Richard
Sabrina Rezzara Richard
JUJosie Ursini-Siegel
Josie Ursini-Siegel
Although effective for immunologically hot tumors, immune checkpoint inhibitors minimally affect tumors that are not T cell inflamed, including breast cancer. An alternate strategy to combat immune cold breast tumors may be to reeducate innate immunity. This study identifies strategies to skew neutrophils to acquire tumoricidal properties. Systemic Toll-like receptor (TLR)–induced inflammation, concomitant with mitochondrial complex I inhibition in breast tumors, increases neutrophil cytotoxicity against breast cancer cells and independently of CD8+ T cell immunity. These therapy-entrained neutrophils enhance secretory granule production, increasing expression of the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase machinery and inducing a respiratory burst. Moreover, systemic administration of TLR agonists elevates nuclear factor κB signaling in neutrophils to increase production of secretory granule and NADPH oxidase machinery components, whereas complex I inhibitors are required to potentiate oxidative damage. In summary, we describe a class of neutrophils, educated by the combined action of inflammatory mediators and metabolic inhibitors, having tumoricidal functions.

13 August 2024 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JHJohn Heath
John Heath
CMCaitlynn Mirabelli
Caitlynn Mirabelli
MAMatthew G. Annis
Matthew G. Annis
VSValerie Sabourin
Valerie Sabourin
SHSteven Hebert
Steven Hebert
JUJosie Ursini-Siegel
Josie Ursini-Siegel
The pogo transposable element–derived zinc finger protein, POGZ, is notably associated with neurodevelopmental disorders through its role in gene transcription. Many proteins involved in neurological development are often dysregulated in cancer, suggesting a potential role for POGZ in tumor biology. Here, we provided experimental evidence that POGZ influences the growth and metastatic spread of triple-negative breast cancers (TNBC). In well-characterized models of TNBC, POGZ exerted a dual role, both as a tumor promoter and metastasis suppressor. Mechanistically, loss of POGZ potentiated TGFβ pathway activation to exert cytostatic effects while simultaneously increasing the mesenchymal and migratory properties of breast tumors. Although POGZ levels are elevated in human breast cancers, the most aggressive forms of TNBC tumors, including those with increased mesenchymal and metastatic properties, exhibit dampened POGZ levels, and low POGZ expression was associated with inferior clinical outcomes in these tumor types. Taken together, these data suggest that POGZ is a critical suppressor of the early stages of the metastatic cascade. Significance: The POGZ neurodevelopmental protein plays dual functions in triple-negative breast cancers as a tumor promoter and metastasis suppressor, inhibiting TGFβ-regulated EMT to limit breast cancer metastatic progression.

17 June 2026
Verified
Other
Open access
JHJohn Heath
John Heath
CMCaitlynn Mirabelli
Caitlynn Mirabelli
MAMatthew G. Annis
Matthew G. Annis
VSValerie Sabourin
Valerie Sabourin
SHSteven Hebert
Steven Hebert
JUJosie Ursini-Siegel
Josie Ursini-Siegel
Supplemental Figure 4 with Legend

17 June 2026
Verified
Other
Open access
JHJohn Heath
John Heath
CMCaitlynn Mirabelli
Caitlynn Mirabelli
MAMatthew G. Annis
Matthew G. Annis
VSValerie Sabourin
Valerie Sabourin
SHSteven Hebert
Steven Hebert
JUJosie Ursini-Siegel
Josie Ursini-Siegel
Supplemental Figure 3 with legend

1 January 2022 in Cancer Immunology Research
Verified
Journal Article
Closed access
JHJohn Heath
John Heath
STStephanie Totten
Stephanie Totten
YIYoung Kyuen Im
Young Kyuen Im
VSValerie Sabourin
Valerie Sabourin
KHKathryn Hunt
Kathryn Hunt
JUJosie Ursini-Siegel
Josie Ursini-Siegel
The tumor microenvironment (TME) is a complex arms race composed of host stroma and rapidly adapting cancer cells. This symbiosis is further complicated when dissecting the influence of inflammation, due to its multifaceted function within the TME as a driver of both pro- and anti-tumor responses. Comprising a major component of the TME, targeting or exploiting tumor-associated inflammation has long been sought for therapeutic purposes. However, the optimal amount and composition of inflammation for such purposes remains elusive. We have recently identified an interferon (IFN)-dependent transcriptional response in breast cancer cells that renders a unique sensitivity to oxidative stress produced by the biguanide-class complex I inhibitor, phenformin. Using syngeneic murine models representing luminal B (PyMT) and basal (4T1) breast cancer, we identified a modest sensitivity to phenformin administration in vivo. However, phenformin effectiveness is dramatically enhanced when used in combination with the toll-like receptor 3 (TLR3) agonist, polyinosinic:polycytidylic acid (poly (I:C)). Critically, the effectiveness of this combination treatment was lost when performed in immune-deficient mice (SCID-beige), indicating that an immune component was essential. These findings highlight a novel role for inflammation and the immune system to promote sensitivity to oxidative stress in the TME. By identifying cell types responsible for cultivating a microenvironment conducive to biguanide sensitivity in breast cancer, we can identify a novel immune-biomarker of complex I sensitivity. Therefore, using high-parameter flow cytometry, we are analyzing systemic and tumor-infiltrating leukocyte diversity and enumeration in both our genetically and phenotypically distinct breast cancer models. Combination-therapy-induced immune populations will be further characterized in their molecular and cellular response to TLR agonism and complex I inhibition. Functional responses such as inflammatory-mediator production, immunomodulatory activity, and direct and indirect tumor cytotoxicity will be assessed, ex vivo. Furthermore, monoclonal antibody-mediated depletion of candidate cell types will be used to validate their requirement and contribution to the observed synergy to the combination therapy. Examples of tumoricidal synergy between biguanides and the inflammatory TLR agonists have not yet been described, establishing these findings as novel additions to the field of tumor biology. Furthermore, identifying how sensitivity to oxidative stress can become situationally immune-dependent can greatly advance our understanding of how inflammation and metabolism intersect within the TME. Citation Format: John Heath, Stephanie Totten, Young Kyuen Im, Valerie Sabourin, Kathryn Hunt, Josie Ursini-Siegel. Driving immune-dependent metabolic vulnerabilities in the breast tumor microenvironment [abstract]. In: Abstracts: AACR Virtual Special Conference: Tumor Immunology and Immunotherapy; 2021 Oct 5-6. Philadelphia (PA): AACR; Cancer Immunol Res 2022;10(1 Suppl):Abstract nr P014.

15 November 2024
Verified
Other
Open access
PDF file
JHJohn Heath
John Heath
CMCaitlynn Mirabelli
Caitlynn Mirabelli
MAMatthew G. Annis
Matthew G. Annis
VSValerie Sabourin
Valerie Sabourin
SHSteven Hebert
Steven Hebert
JUJosie Ursini-Siegel
Josie Ursini-Siegel
Supplemental Figure 2 with legend